PE firm continues investments in health care industry by taking a stake in Jaggaer

By Maggie Lynch contact

- Last updated on GMT

(Image: Getty/FeelPic)
(Image: Getty/FeelPic)

Related tags: PE, Investment, Health care, Software, Medpace, Bioclinica, acquistion

The strategic sourcing software company Jaggaer has received an investment from international PE firm Cinven.

Cinven will support Jaggaer’s management and operations as it plans to increase assets and capabilities in its spend management suite, The Jaggaer One platform.

According to Jaggaer, the platform uses machine learning and artificial intelligence (AI) capabilities in its network of 4m suppliers to simplify the contracting process for clients taking on existing and potential customers.

Chris Good, partner and co-head of Cinven’s technology, media, and telecom (TMT) team, said in a statement, “As a growing and profitable spend management software business with a very strong track record, and following a number of successful acquisitions, the business is poised for continued significant growth.”

No financial terms of this investment were disclosed.

The UK-based private equity (PE) company has raised a total of €37bn and invested in 135 companies across Europe and North America. The investment in Jaggaer follows investments in Medpace​ in 2014 and Bioclinica​ in 2016.

Related news

Show more

Related products

RACE Act Prompts Pediatric Oncology Trials

RACE Act Prompts Pediatric Oncology Trials

PRA Health Sciences | 04-May-2020 | Technical / White Paper

Many providers prescribe drugs off-label to pediatric patients, even though there have been few pediatric trials for many of these drugs. In response,...

Global Clinical Trial Lab Services

Global Clinical Trial Lab Services

Q2 Solutions | 01-Apr-2020 | Product Presentation

As a leading global lab services partner, we provide operational excellence, scientific leadership and innovation through technology. We offer end-to-end...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 01-Mar-2020 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

Related suppliers

Follow us


View more